"What separates SPPH from competitors is that they're not primarily focused on the time-release, but the efficiency of the delivery of the drug.
If less amounts need to be taken, the side effects will be mild.
Reduced dosage all the way!"
And what do the human studies that will need to be done before any product using SPPH's modified-release technology can be approved anywhere in the world, including the US and Canada, show about side-effects and efficacy?
Oh, that's right, there aren't any human studies. I'm surprised that SPPH didn't ask their paid stock promoters on this message board to mention this highly relevant fact in their puff pieces on behalf of Spencer Pharmaceuticals.
FDA and SEC rather think that that sort of information should be disclosed.
News 
Market Data 
Discover 
AI
